Potential Clinical Benefits And Probable Mechanisms of Action Promoted By A Nutraceutical Obtained By Fermentation And Rich In Β-Glucans And Amino Acids for Oncologic Patients
-
Published:2024-01-10
Issue:00
Volume:3
Page:e055
-
ISSN:2764-9512
-
Container-title:Journal of Medical Residency Review
-
language:
-
Short-container-title:jmrr
Author:
Fernandes Junior Hezio Jadir,Tallo Fernando Sabia,Góes Rafael Batman de,Ferraz de Oliveira Carolina Trabasso,Nicolau Lucas Antonio Duarte,Arias Alexia Nascimento,Viana Bianca Lorayne de Almeida,Menezes-Rodrigues Francisco Sandro
Abstract
Cancer patients are generally submitted to chemotherapy and radiotherapy, which tend to cause problems related to intense inflammatory processes, malnutrition, nausea, and emesis. Therefore, performing supplementation in these patients is important and necessary, as it favors cancer patients from a nutritional point of view. Amino acids and β-glucans obtained from fermentation processes proved to be important in the care of cancer patients because they improve the nutritional parameters and general condition of the patient. We aim to discuss the benefits obtained by cancer patients undergoing chemotherapy and radiotherapy who received supplementation with a fermented nutraceutical rich in β-glucans and amino acids. A literature review was carried out through an active search for scientific articles by the following descriptors in Portuguese: “nutraceutical”, “β-glucans”, “oncological patients”. In addition, we also discuss the benefits caused using the product called BionutriAR1®, a nutraceutical that contributes to the recovery of nutritional status. We conclude that the use of products capable of promoting supplementation of β-glucans and amino acids is beneficial to cancer patients, especially those undergoing chemotherapy and radiotherapy and, therefore, there is an indication of supplementation for these patients with the fermented product BionutriAR1®.
Publisher
Editora Alumniin
Reference64 articles.
1. Jamal-Hanjani, M.; Wilson, G. A.; McGranahan, N.; Birkbak, N. J.; Watkins, T.; Veeriah, S.; Shafi, S.; Johnson, D. H., Mitter, R., Rosenthal, R., Salm, M., Horswell, S., Escudero, M., Matthews, N., Rowan, A., Chambers, T., Moore, D. A., Turajlic, S., Xu, H., Lee, S. M., … TRACERx Consortium. Tracking the Evolution of Non–Small-Cell Lung Cancer. New England Journal of Medicine 2017, 376, 2109–2121. 2. Sagar, B.; Lin, Y.S.; Castel, L.D. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective. Journal of Medical Economics 2017, 20, 1018–1023. 3. Morigi, C. Highlights from the 15th St Gallen International Breast Cancer Conference, Vienna: tailored treatments for patients with early breast cancer. Ecancermedicalscience 2017, 11, 732. 4. Carling, D. AMPK signalling in health and disease. Current Opinion in Cell Biology 2017, 45, 31–37. 5. Errante, P.R.; Neto, A.C.; Bergantin, L. B. Insights for the inhibition of cancer progression: Revisiting Ca2+ and cAMP signalling pathways. Advances in Cancer Prevention 2017, 2, e103.
|
|